Valuation: Precision BioSciences, Inc.

Market Cap 205M 177M 166M 152M 285M 19.53B 289M 1.96B 764M 9.78B 769M 752M 32.61B P/E 2026 *
-1.91x
P/E 2027 * -2.74x
Enterprise Value 205M 177M 166M 152M 285M 19.53B 289M 1.96B 764M 9.78B 769M 752M 32.61B EV / Sales 2026 *
16.8x
EV / Sales 2027 * 21.4x
Free-Float
93.72%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Precision BioSciences, Inc.

1 day-1.20%
1 week-0.67%
Current month+6.15%
1 month-15.30%
3 months-9.51%
6 months+87.37%
Current year+78.37%
1 week 7.32
Extreme 7.325
7.76
1 month 6.7
Extreme 6.7
8.96
Current year 3.53
Extreme 3.53
9.62
1 year 3.53
Extreme 3.53
9.62
3 years 3.53
Extreme 3.53
19.43
5 years 3.53
Extreme 3.53
431.4
10 years 3.53
Extreme 3.53
710.11
Manager TitleAgeSince
Chief Executive Officer 48 15/10/2021
Chief Tech/Sci/R&D Officer 53 26/01/2006
Director of Finance/CFO 45 01/08/2026
Director TitleAgeSince
Chairman 68 01/11/2020
Director/Board Member 65 10/03/2020
Director/Board Member 67 12/04/2021
Date Insider Type Main position Quantity % Market Cap.
01/08/26 Other

Chief Financial Officer

251,581 1.0451%
01/08/26 Other

Controller/Auditor

48,872 0.2030%
01/08/26 Other

Chief Technology Officer

236,188 0.9812%
Change 5-day change 1-year change 3-year change Capi.($)
-1.20%-0.67%+69.41%-53.77% 205M
+0.67%+0.78%+3.71%+15.54% 48.72B
-0.14%+4.03%+482.13%+584.43% 43.99B
-0.06%+9.62%+24.63%+81.63% 40.82B
-0.87%+2.40%+30.01%+9.95% 39.79B
-4.04%+6.15%+23.03%+48.00% 32.7B
-1.41%+1.57%+29.98%+123.68% 16.66B
+0.35%+4.61% - - 16.84B
+0.92%+0.52%+5.15%+21.82% 13.95B
+0.84%+9.07%+86.17%+32.60% 13.58B
Average -0.50%+3.50%+83.80%+95.99% 26.72B
Weighted average by Cap. -0.51%+3.93%+104.23%+138.03%

Financials

2026 *2027 *
Net sales 12.16M 10.53M 9.87M 9M 16.93M 1.16B 17.19M 116M 45.38M 581M 45.65M 44.66M 1.94B 9.58M 8.3M 7.77M 7.09M 13.33M 913M 13.53M 91.42M 35.73M 457M 35.95M 35.17M 1.52B
Net income -98.98M -85.76M -80.35M -73.29M -138M -9.44B -140M -945M -369M -4.73B -372M -364M -15.76B -89.14M -77.23M -72.36M -66M -124M -8.5B -126M -851M -333M -4.26B -335M -327M -14.19B
Net Debt - -
Logo Precision BioSciences, Inc.
Precision BioSciences, Inc. is a clinical-stage gene editing company dedicated to improving life (DTIL) with its proprietary ARCUS genome editing platform. Using ARCUS, the Company’s pipeline is comprised of in vivo gene editing candidates designed to deliver cures for a range of genetic and infectious diseases. The ARCUS platform is used to develop in vivo gene editing therapies for gene edits, including gene insertion, elimination, and excision. The Company's in vivo gene editing pipeline programs include PBGENE-HBV, PBGENE-3243, PBGENE-DMD, PBGENE-LIVER, PBGENE-CNS, PBGENE-NVS and iECURE-OTC. PBGENE-HBV is its lead in vivo gene editing program designed to eliminate cccDNA, the key source of replicating hepatitis B virus (HBV) and inactivating integrated HBV DNA in hepatocytes. Its PBGENE-3243 program is a first of its kind potential treatment for m.3243 associated mitochondrial disease. The Company's iECURE-OTC program is developed in partnership with iECURE, Inc.
Employees
67
Date Price Change Volume
12/08/26 $7.420 -1.20% 268,142
11/08/26 $7.510 +0.67% 345,173
10/08/26 $7.460 -0.40% 192,067
07/08/26 $7.490 +0.94% 240,108
06/08/26 $7.420 -0.67% 328,717
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
7.420USD
Average target price
29.40USD
Spread / Average Target
+296.23%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. DTIL Stock